Posted: 2:02 pm Thu, May 30, 2013
By Daily Record Staff
PharmAthene Inc., of Annapolis, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Food and Drug Administration has lifted a nearly-10-month hold placed on a proposed Phase II study of SparVax, allowing a clinical trial of the next-generation anthrax vaccine to proceed.
Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.